相关实验视频

Updated: Jul 14, 2026

Polysome Profiling in Leishmania, Human Cells and Mouse Testis

Polysome Profiling in Leishmania, Human Cells and Mouse Testis

Published on: April 8, 2018

莱什马尼亚调节宿主YY1:比较蛋白质组分析确定了感染调节的YY1依赖蛋白

Harsimran Kaur Brar¹, Eleanor Chen¹, Fabian Chang¹

¹Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

|May 15, 2025

概括

转录因子阴阳1 (YY1) 促进了Leishmania寄生虫在巨细胞中的生存. 抑制YY1 的作用

科学领域:

免疫学免疫学免疫学
分子生物学分子生物学
寄生虫学的寄生虫学

背景情况:

阴阳1 (YY1) 是一种多功能转录因子,在各种细胞过程中发挥作用.
莱什曼尼病是一种由莱什曼尼亚寄生虫引起的疾病,在全球范围内影响着数百万人.
宿主因子,如YY1在莱什曼尼亚病变发生过程中的作用尚未完全理解.

研究的目的:

研究巨细胞阴阳1 (YY1) 在莱什曼尼亚寄生虫细胞内生存中的作用.
阐明YY1通过哪些机制影响Leishmania在宿主细胞内的持久性.

主要方法:

感染莱什曼病的巨细胞培养物.
使用RNA干扰的YY1淘汰实验.
生物化学分化研究YY1局部化.
莱普托米辛B治疗以抑制核运输.
没有标签的定量全蛋白质组分析.

主要成果:

淘汰YY1显著降低了巨细胞中的Leishmania存活率.
莱什曼尼亚感染诱导了YY1从细胞核到细胞质的再分配.
抑制核运输阻断了YY1的再分配,并降低了寄生虫的生存率.
蛋白质组分析显示,YY1调节了许多宿主蛋白质,其中许多蛋白质在Leishmania感染期间被调节.

结论:

YY1 是一个关键的宿主因子,促进莱什曼尼亚细胞内生存.
莱什曼尼亚操纵YY1局部化,有利于其在巨细胞内的持久性.
依赖YY1的宿主蛋白调节是莱什马尼亚病变发生的关键机制.
YY1代表了抗莱什曼病治疗的新潜在目标.

更多相关视频

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Published on: October 28, 2022

相关概念视频

Leishmaniasis

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...